SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

News Release

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

May 12, 2025 —  SOLVD Health has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company’s continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform.

Aicher’s expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executive experience in genomics, laboratory medicine, and diagnostics innovation. He co-founded and served as CEO of the National Genetics Institute (NGI) — acquired by Labcorp (NYSE: LH) — where he later led the company’s Esoteric Business Units, which generated over $1 billion in annual revenue. He currently serves as Executive Chairman of SemiconBio and on the board of Genetic Signatures (ASX: GSS) and Techcyte. He holds a bachelor’s degree in business administration from the University of Redlands and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.

Cebula’s deep financial acumen and board leadership will help guide SOLVD Health’s expansion and long-term sustainability. An accomplished investor and advisor with extensive experience in private equity, investment banking, and operational transformation, he was a senior asset management executive focused on providing capital to lower middle market companies in the United States and Canada and has served on over fifteen private and public company boards. Cebula has held senior roles at Oaktree Capital Management, Jefferies Capital Partners, and Drexel Burnham Lambert, with a focus on strategic growth and value creation, and graduated from The Wharton School of The University of Pennsylvania.

“As we advance the next phase of our mission — bringing personalized, precision insights to more patients and providers — Mike and Vincent bring the experience and strategic vision to help us scale our impact,” said Dr. Keri Donaldson, Founder and CEO of SOLVD Health. “Mike’s contributions to diagnostics innovation and Vincent’s financial and operational leadership will be instrumental as we grow our platform and deepen our ability to deliver better health outcomes through data.”

These board appointments come at a pivotal time for SOLVD Health as it advances its proprietary diagnostics platform, including the FDA-approved AvertD® test for assessing the genetic risk of opioid use disorder (OUD). With Aicher and Cebula’s assistance, the company is well-positioned to deepen its clinical impact, expand strategic partnerships, and further its mission to prevent disease through data-driven, patient-centered innovation.

About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health.

Media Contact:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

SOLVD Health Receives New York State Laboratory Approval

SOLVD Health Receives New York State Laboratory Approval

News Release

SOLVD Health Receives New York State Laboratory Approval

SAN DIEGO–(BUSINESS WIRE)–SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has received approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for its San Diego-based laboratory. This approval authorizes SOLVD Health to offer AvertD® for patients in New York, empowering healthcare providers and patients with critical insights to help mitigate the risk of opioid use disorder (OUD).

The New York State Department of Health is recognized for its rigorous standards in clinical laboratory testing, ensuring that approved laboratories meet high benchmarks for accuracy, reliability, and patient safety. SOLVD Health’s AvertD®genetic test, already FDA-approved, is designed to assess individual genetic susceptibility to OUD, providing valuable information to guide personalized pain management strategies.

“Securing New York State approval is a pivotal step in our mission to expand access to genetic testing that can help address the opioid crisis,” said SOLVD Health founder and CEO Dr. Keri Donaldson. “This expansion enables more healthcare providers and patients to benefit from personalized health insights that can inform decisions about pain management and potentially prevent adverse outcomes.”

As the healthcare industry continues to seek solutions to combat the ongoing opioid epidemic, AvertD offers clinically validated genetic insights that can help them advise pain management decisions before opioid therapy begins. This approval advances SOLVD Health’s mission to translate complex biological signals into actionable patient data, empowering individuals and healthcare providers to make more informed health decisions.

About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health.

Media Contact:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

SOLVD Health to Present at William Blair’s Innovator Series

News Release

SOLVD Health to Present at William Blair’s Innovator Series: Life Science Tools and Diagnostics

SAN DIEGO–(BUSINESS WIRE)–SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, announced today that its Founder and CEO, Dr. Keri Donaldson, will provide a company update and participate in a virtual fireside chat at William Blair’s Innovator Series: Life Science Tools and Diagnostics.

Dr. Donaldson’s presentation will take place on Tuesday, December 17, 2024, from 1:00 p.m. to 1:45 p.m. ET. The session will include a company update followed by a Q&A with William Blair’s Diagnostics Analyst, Andrew Brackmann. Together, they will discuss SOLVD Health’s advancements, ongoing initiatives, and the company’s vision for transforming health outcomes through innovative genetic and AI-driven tools.

William Blair’s Innovator Series is a premier virtual event that highlights some of the most dynamic and fast-growing private companies in the life science tools and diagnostics space.

The event provides investors with the opportunity to learn directly from industry leaders about cutting-edge advancements shaping the future of healthcare.

Event Details:

  • Date: Tuesday, December 17, 2024
  • Time: 1:00 p.m. – 1:45 p.m. ET
  • Location: Virtual

“We’re excited to share SOLVD Health’s progress and innovative approach to enhancing personalized health outcomes,” said Dr. Keri Donaldson. “This series is an important platform for showcasing the transformative potential of precision health solutions.”

For more information about the William Blair Innovator Series, visit the event page link.

About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health.

Media Contact:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

SOLVD Health Receives New York State Laboratory Approval

SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test

News Release

SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test

SAN DIEGO–(BUSINESS WIRE)–SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has launched a comprehensive post-approval study for AvertD®, the first U.S. Food and Drug Administration (FDA)-approved genetic test for assessing risk of developing opioid use disorder (OUD). This post-approval study aims to expand upon pivotal study findings and further demonstrate AvertD’s ability to enhance personalized data-driven decisions in real-world settings.

e prospective study will enroll up to 4,000 patients, integrating agile methods to gather comprehensive, real-world data from diverse demographic groups across the United States. Designed to confirm AvertD’s predictive accuracy across diverse populations, the study seeks to equip providers with critical insights for individualized, evidence-based pain management.

“The launch of our post-approval study for AvertD represents more than our commitment to regulatory requirements. It’s a commitment to addressing one of the most pressing public health challenges of our time,” said SOLVD Health Founder and CEO Dr. Keri Donaldson. “Every day, healthcare providers and their patients face challenging decisions about pain management. Our goal is to arm them with precise, personalized insights to guide these critical decisions and improve patient outcomes.”

The study will follow participants for up to five years, providing additional long-term data on the predictive value of genetic testing in OUD risk assessment. The extended timeframe will enable researchers to observe how genetic risk factors interact with environmental and behavioral influences over time, potentially uncovering new strategies for addiction prevention and intervention.

About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health.

Media Contact:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

SOLVD Health Receives FDA PMA Supplement Approval for Use of INFINITI High-Throughput System with AvertD®

News Release

SOLVD Health Receives FDA PMA Supplement Approval for Use of INFINITI High-Throughput System with AvertD®

SAN DIEGO–(BUSINESS WIRE)–SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has received U.S. Food and Drug Administration (FDA) PMA supplement approval for its INFINITI High Throughput System (HTS) to be used with AvertD®.

The HTS instrument expands daily processing capacity, designed to work seamlessly with SOLVD Health’s entire test portfolio, including AvertD®, the first FDA-approved genetic test for assessing elevated risk for developing opioid use disorder (OUD). The development marks a major advancement in SOLVD Health’s ability to deliver critical health insights at scale.

“This system is about more than increasing output. It’s about amplifying our impact,” said SOLVD Health Founder and CEO Dr. Keri Donaldson. “With the HTS, we’re enabling access to cutting-edge genetic insights and opening new possibilities for personalized medicine and preventive health care.”

The HTS underwent rigorous FDA evaluation to ensure it produces results consistent with the organization’s already approved INFINITI PLUS Analyzer. The HTS is a semi-automated, scalable, and multiplexed microarray analysis system that increases throughput to 960 samples in approximately 8 hours compared to 48 samples on the INFINITI PLUS. This efficiency, combined with the cost-effective and readily available DNA processing equipment, significantly enhances workflow optimization.

“This approval underscores our commitment to innovation and clinical excellence,” added Dr. Donaldson. “We’re poised to make a broader impact on critical health issues, including the opioid crisis, by making advanced genetic insights more accessible to health care providers and patients.”

The approval marks another milestone in SOLVD Health’s mission to translate complex biological signals into actionable patient data, empowering individuals and health care providers to make more informed health decisions.

About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health.

Media Contact:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

SOLVD Health Receives New York State Laboratory Approval

SOLVD Health Names Chief Financial Officer and Senior Vice President of Clinical Operations

News Release

SOLVD Health Names Chief Financial Officer and Senior Vice President of Clinical Operations

CARLSBAD, Calif.–(BUSINESS WIRE)–SOLVD Health, a patient intelligence company focused on creating innovative technologies that identify an individual’s risk of disease by discovering and converting biological signals into predictive, contextual health insights, has appointed Mark Hazeltine as Chief Financial Officer and Ron McCullough as Senior Vice President of Clinical Operations.

Mr. Hazeltine has extensive experience in finance, operations, and strategic development. Before joining SOLVD Health, he served as Chief Business Officer at Exagen Inc., a diagnostics company specializing in autoimmune testing. At Exagen, Mr. Hazeltine held various roles in finance and corporate development, including Senior Vice President of Finance & Corporate Development, General Manager and Chief Operating Officer. He co-led the IPO process and significantly increased reimbursement rates through improved billing processes. Mr. Hazeltine holds a Bachelor of Business Administration from the University of San Diego and a Master of Business Administration from the University of Southern California.

“Mark’s proven track record of driving change, fostering growth, and providing strategic financial leadership in both startup and established healthcare organizations makes him the ideal addition to our executive team,” said SOLVD Health founder and CEO Keri Donaldson. “His deep understanding of the diagnostics industry, combined with his successful IPO experience, fundraising, and operational excellence, will be invaluable as we continue to scale our business and pursue our mission.”

Dr. McCullough is a seasoned executive with a strong background in commercializing high-potential research, clinical diagnostics, and business innovation. He served as the Chief Scientific Officer and co-founder at Intrigue Health, a medical device and digital health startup. Dr. McCullough also chaired the Strategic Advisory Board at Claire Health and served as Senior Vice President of Operations at Pathnostics. He holds a Doctor of Philosophy in molecular and cellular biology and biochemistry from Boston University, a Master of Business Administration from the University of San Diego, and a Bachelor of Science in chemistry and biochemistry from the University of Arizona.

“Ron brings a unique blend of scientific expertise, business acumen, and entrepreneurial spirit to our team,” added Dr. Donaldson. “His experience leading cross-functional teams and driving successful product development and commercialization will help us accelerate our growth and solidify our position as a leader in the industry.”

These additions come at a critical time for SOLVD Health. In December, the U.S. Food and Drug Administration approved the company’s AvertD test, making it the first genetic test authorized to assess the risk of opioid use disorder (OUD) prior to initiating opioid therapy for acute pain management. AvertD empowers physicians and patients to make more informed decisions about pain management options, supporting SOLVD Health’s mission to address pressing healthcare challenges through innovative solutions.

About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, we are enabling individuals and their providers to make better decisions about their health and the health of their families. We accomplish this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about us, our solutions, and our career opportunities, visit us at www.solvdhealth.com.

Contacts

Media:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com